Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (81-90 of 662) with videos related to

Pageof 67
Sort By:
Leukemia & Lymphoma|August 9, 2005
CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectivesWolfgang R Sperr, Stefan Florian, Alexander W Hauswirth, et al.
Veterinary Medicine and Science|September 14, 2020
In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cellsSusanne Gamperl, Gabriele Stefanzl, Michael Willmann, et al.
Atherosclerosis|July 21, 2017
Peripheral arterial disease outcomes and association with suPAR: A bridge to myeloid precursors or mast cells or both?Clemens Hoebaus, Sarah Mohammed Yussuf, Peter Valent, et al.
The Journal of Allergy and Clinical Immunology|July 9, 2004
Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasmsPeter Valent, Wolfgang R Sperr, Lawrence B Schwartz, et al.
Leukemia & Lymphoma|May 27, 2004
Bone marrow mastocytosis associated with IgM kappa plasma cell myelomaFlorian Stellmacher, Karl Sotlar, Leopold Balleisen, et al.
Leukemia Research|June 21, 2005
Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomibMaria-Theresa Krauth, Alexander Bankier, Peter Valent, et al.
American Journal of Hematology|March 26, 2013
Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?Andres Wiernik, Wolfgang R Sperr, Daniel Weisdorf, et al.
Wiener Klinische Wochenschrift|September 19, 2003
Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS)Peter Valent, Friedrich Wimazal, Ilse Schwarzinger, et al.
International Archives of Allergy and Immunology|November 30, 2011
Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experienceFriedrich Wimazal, Philipp Geissler, Patrik Shnawa, et al.
Haematologica|October 7, 2017
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinibKonstantin Byrgazov, Chantal Blanche Lucini, Peter Valent, et al.
Pageof 67

Showing results (81-90 of 662) with videos related to

Sort By:
Pageof 67
Leukemia & Lymphoma|August 9, 2005
CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectivesWolfgang R Sperr, Stefan Florian, Alexander W Hauswirth, et al.
Veterinary Medicine and Science|September 14, 2020
In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cellsSusanne Gamperl, Gabriele Stefanzl, Michael Willmann, et al.
Atherosclerosis|July 21, 2017
Peripheral arterial disease outcomes and association with suPAR: A bridge to myeloid precursors or mast cells or both?Clemens Hoebaus, Sarah Mohammed Yussuf, Peter Valent, et al.
The Journal of Allergy and Clinical Immunology|July 9, 2004
Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasmsPeter Valent, Wolfgang R Sperr, Lawrence B Schwartz, et al.
Leukemia & Lymphoma|May 27, 2004
Bone marrow mastocytosis associated with IgM kappa plasma cell myelomaFlorian Stellmacher, Karl Sotlar, Leopold Balleisen, et al.
Leukemia Research|June 21, 2005
Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomibMaria-Theresa Krauth, Alexander Bankier, Peter Valent, et al.
American Journal of Hematology|March 26, 2013
Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?Andres Wiernik, Wolfgang R Sperr, Daniel Weisdorf, et al.
Wiener Klinische Wochenschrift|September 19, 2003
Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS)Peter Valent, Friedrich Wimazal, Ilse Schwarzinger, et al.
International Archives of Allergy and Immunology|November 30, 2011
Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experienceFriedrich Wimazal, Philipp Geissler, Patrik Shnawa, et al.
Haematologica|October 7, 2017
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinibKonstantin Byrgazov, Chantal Blanche Lucini, Peter Valent, et al.
Pageof 67